Palatin Technologies, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended December 31, 2019 (fiscal 2020 second quarter). Financial statements are unaudited.
Business context and key financial metrics
Palatin is a clinical-stage biopharmaceutical company developing therapies targeting melanocortin and natriuretic peptide receptors. Its lead product, Vyleesi for HSDD in premenopausal women, was FDA-approved in June 2019 and marketed in North America by licensee AMAG. Development programs include MC1r, MC4r and natriuretic peptide candidates.
| Metric | Three months ended Dec. 31, 2019 | Six months ended Dec. 31, 2019 | Comparable 2018 period |
|---|---|---|---|
| Revenue | $20,610 | $117,989 | $0 and $34,505, respectively |
| Research and development | $3.26 million | $6.39 million | $2.96 million and $6.58 million |
| General and administrative | $2.40 million | $4.24 million | $2.09 million and $4.13 million |
| Net loss | $5.24 million | $9.74 million | $5.04 million and $10.72 million |
| Loss per share, basic and diluted | $0.02 | $0.04 | $0.02 and $0.05 |
Revenue consisted of AMAG-related license and contract billings; the filing reports no material product sales or royalty revenue for these periods. Operating margins are not meaningful given the very low revenue and continuing development-stage losses.
At December 31, cash and cash equivalents were $91.46 million, total current assets were $92.23 million, current liabilities were $1.37 million, and total liabilities were $1.39 million. The company reported no notes payable at period end; its venture debt had been repaid by July 2019. Six-month operating cash flow was positive $49.91 million, primarily reflecting a $60.15 million reduction in accounts receivable and timing of AMAG-related receipts. Cash rose $47.95 million from June 30, 2019. Six-month investing cash use was $62,880 and financing cash use was $1.90 million.
Material changes versus prior comparable periods
- Six-month net loss narrowed to $9.74 million from $10.72 million, while quarterly net loss increased to $5.24 million from $5.04 million.
- Six-month R&D expense decreased modestly, partly due to lower stock-based compensation, while quarterly R&D increased, primarily from higher PL8177 spending.
- Investment income increased as the company held more cash, and interest expense declined following repayment of venture debt.
- Operating cash flow swung from $11.03 million used in the prior-year half to $49.91 million provided, largely due to collections/timing of AMAG-related receivables; this should not be read as recurring operating cash generation.
- Common shares outstanding were 229.17 million at December 31, compared with 226.82 million at June 30. The company also repurchased and canceled 6.54 million warrants for $2.55 million during the six-month period.
Outlook, commentary, risks and unusual items
- Management said existing capital resources were expected to fund planned operations through at least calendar year 2021, but additional funding would be needed for required clinical trials and subsequent regulatory submissions. Profitability remains uncertain.
- An IND for PL9643 in dry eye disease was filed in December 2019; a Phase 2 study was expected to begin in the first quarter of calendar 2020. A Phase 2 proof-of-concept study of PL8177 in ulcerative colitis was anticipated in mid-2020. These are forward-looking plans, not reported outcomes.
- On January 9, 2020, after quarter-end, AMAG announced plans to divest Vyleesi and another women’s-health product. Palatin said the announcement created uncertainty about North American commercialization; no potential Vyleesi buyer or sublicensee had been publicly identified. A capable successor or transition is not assured.
- Palatin may have termination rights if AMAG materially breaches its commercialization obligations. If Palatin regains the rights, it would need to establish or arrange sales, manufacturing, distribution and related capabilities, which could be costly and time-consuming.
- General and administrative expense included a final $625,000 payment to Greenhill following termination of its advisory engagement; Palatin reported no further payment obligations to Greenhill.
- The company adopted the lease accounting standard in July 2019, recording a $225,134 operating lease asset and liability at adoption, with no material impact on operations or cash flows. No material legal proceedings or off-balance-sheet arrangements were reported.
Important facts for investors to verify
- AMAG’s divestiture process, the identity and capability of any successor, and the effect on Vyleesi marketing, sales and royalties.
- Whether AMAG-related receivables and cash collections are one-time timing effects, and whether future royalties or sales milestones materialize.
- Progress and actual timing of the PL9643 and PL8177 clinical programs, including trial starts and funding needs.
- Cash burn and runway relative to management’s stated through-2021 estimate, especially as development spending continues.
- Potential dilution from equity issuance, outstanding options, restricted stock units and warrants; the filing reported an at-the-market equity program and ongoing warrant repurchases.